Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paroxysmal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    204 result(s) found for: Paroxysmal. Displaying page 6 of 11.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2016-004505-13 Sponsor Protocol Number: TOFFIFE Start Date*: 2017-11-27
    Sponsor Name:University Hospital Tuebingen
    Full Title: Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE
    Medical condition: Adult patients with Familial Mediterranean Fever, who have active disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003894-26 Sponsor Protocol Number: 1160.26 Start Date*: 2005-12-23
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke...
    Medical condition: Prevention of Stroke and Systemic Embolism in patients with Atrial Fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) CZ (Completed) AT (Completed) HU (Completed) DE (Completed) SK (Completed) IT (Completed) ES (Completed) GB (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019009-40 Sponsor Protocol Number: A7331010 Start Date*: 2010-07-08
    Sponsor Name:Pfizer, S.A.
    Full Title: Estudio clínico de Fase 2A, multicéntrico aleatorizado, doble ciego, controlado con placebo y con un fármaco activo, de diseño cruzado con dos cohortes y dos dosis, para la evaluación de la eficaci...
    Medical condition: Tratamiento del vasospasmo en el fenómeno de Raynaud primario y secundario.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037912 Raynaud's phenomenon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000888-33 Sponsor Protocol Number: CLNP023X2201 Start Date*: 2018-02-05
    Sponsor Name:Novartis Pharma AG
    Full Title: An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with p...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10018911 Haemolyses and related conditions HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004337-33 Sponsor Protocol Number: APAF/01 Start Date*: 2004-11-12
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: RANDOMIZED COMPARISON OF CIRCUMFERENTIAL PULMONARY VEIN ABLATION VERSUS ANTIARRHYTHMIC THERAPY FOR CURING PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION. (APAF STUDY)
    Medical condition: APPLICATION OF CIRCUMFERENTIAL PULMONARY VEIN ABLATION IN THE TREATMENT OF PAROXYSMAL ATRIAL FIBRILLATION
    Disease: Version SOC Term Classification Code Term Level
    6.1 10007541 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003395-72 Sponsor Protocol Number: VitD@BPPV Start Date*: 2016-11-29
    Sponsor Name:Hospital of the University of Munich
    Full Title: Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind study (VitD@BPPV)
    Medical condition: The main symptoms of Benign Paroxysmal Positional Vertigo (BPPV) are brief, in part strong attacks of rotatory vertigo lasting seconds. These attacks can be provoked by reclination of the head or t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004291-35 Sponsor Protocol Number: CACZ885N2301 Start Date*: 2014-05-16
    Sponsor Name:Novartis Farma SpA
    Full Title: A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency redu...
    Medical condition: Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10067783 Tumor necrosis factor receptor-associated periodic syndrome LLT
    16.1 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    16.1 10010331 - Congenital, familial and genetic disorders 10072010 Hyper IgD syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) IE (Completed) DE (Completed) BE (Completed) HU (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000902-82 Sponsor Protocol Number: D8000-003 Start Date*: 2022-05-24
    Sponsor Name:Alzecure Pharma AB
    Full Title: A Phase 2a, randomised, double-blind, placebo-controlled crossover study to explore the effects of ACD440 in patients with peripheral neuropathic pain with sensory hypersensitivity
    Medical condition: Peripheral neuropathic pain with sensory hypersensitivity
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10077974 Peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019247-19 Sponsor Protocol Number: DRONE_C_04629 Start Date*: 2010-10-12
    Sponsor Name:sanofi aventis groupe
    Full Title: A Randomized, international, multi-center, open-label study to document pharmacokinetics and optimal timing of initiation of dronedarone TreatmEnt following long-term aMIodarone in patients with pa...
    Medical condition: Paroxysmal or persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) FR (Completed) DE (Completed) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001453-10 Sponsor Protocol Number: BA41510 Start Date*: 2019-09-16
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, LOW-INTERVENTIONAL STUDY DOCUMENTING THE EFFICACY, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY OF STANDARD-OF-CARE TREATMENT WITH ECULIZUMAB OR TREATMENT WITH RAVULIZUMAB IN PATIENTS ...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) that is treated with either eculizumab or ravulizumab as per local label
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003698-42 Sponsor Protocol Number: D1250C00012 Start Date*: 2008-11-21
    Sponsor Name:AstraZeneca AB
    Full Title: A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin...
    Medical condition: the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) SK (Completed) DE (Completed) HU (Prematurely Ended) ES (Prematurely Ended) FR (Ongoing) DK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003203-35 Sponsor Protocol Number: VP-C21-004 Start Date*: 2019-12-13
    Sponsor Name:Vicore Pharma AB
    Full Title: A Phase 2, single-center, randomised, double-blind, placebo-controlled, cross-over, cold challenge study investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud’s ...
    Medical condition: Systemic sclerosis (SSc) Raynaud’s phenomenon (RP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-005744-34 Sponsor Protocol Number: iCHF-2 Start Date*: 2019-01-03
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency
    Medical condition: Patients With Cardiovascular Disease and Concomitant Iron Deficiency Cohort A: Acute myocardial infarction (AMI) Cohort B: Paroxysmal atrial fibrillation or persitent atrial fibrillation (AF) Coho...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10071667 Persistent atrial fibrillation LLT
    20.0 10007541 - Cardiac disorders 10034039 Paroxysmal atrial fibrillation LLT
    20.0 10022891 - Investigations 10050527 Ejection fraction PT
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004817-33 Sponsor Protocol Number: EFC10295 Start Date*: 2008-02-19
    Sponsor Name:sanofi-aventis recherche&développement
    Full Title: A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjuste...
    Medical condition: The subjects who will participate to this clinical trial are not healthy volonteers. They have Permanent, persistent or paroxysmal non-valvular atrial fibrillation that is ECG-documented, with an i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) ES (Completed) FI (Completed) EE (Completed) GR (Prematurely Ended) DK (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SK (Completed) PT (Completed) BG (Completed) IT (Prematurely Ended) LT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000306-29 Sponsor Protocol Number: 20103 Start Date*: 2021-10-04
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NY...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) AT (Completed) HU (Completed) BG (Completed) PT (Completed) NL (Completed) SK (Completed) GR (Completed) CZ (Completed) LT (Completed) FI (Completed) LV (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-005437-38 Sponsor Protocol Number: D1250C00008 Start Date*: 2007-03-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of...
    Medical condition: Paroxysmal, persistent or permanent nonvalvular atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001013-32 Sponsor Protocol Number: CV-185-685 Start Date*: 2018-11-08
    Sponsor Name:HOSPITAL CLÍNIC BARCELONA
    Full Title: ANTITHROMBOTIC THERAPY AFTER LEFT ATRIAL APPENDAGE OCCLUSION: DOUBLE ANTIPLATELET THERAPY VS. APIXABAN
    Medical condition: ATRIAL FIBRILLATION IN PATIENTS AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002262-37 Sponsor Protocol Number: ATP1 Start Date*: 2004-10-27
    Sponsor Name:Newcastle Hospitals Trust
    Full Title: Adenosine testing in the diagnosis of unexplained syncope: A pilot study
    Medical condition: Syncope
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002236-14 Sponsor Protocol Number: BI1160.206 Start Date*: 2015-10-28
    Sponsor Name:University Hospital Ulm
    Full Title: Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study
    Medical condition: left atrial thrombus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-004136-26 Sponsor Protocol Number: S67063 Start Date*: 2023-06-28
    Sponsor Name:KU Leuven/UZ Leuven
    Full Title: Pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation
    Medical condition: Stroke prevention in atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10016566 Fibrillation atrial LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:49:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA